Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Schedule of basic and diluted net loss per share

Basic and diluted net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. was calculated as follows:


	Three Months Ended March 31,
	2021		2020
Numerator:
Net loss	$	(265,328)	$	(172,937)
Net loss attributable to non-controlling interests	(360)		—
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(264,968)	$	(172,937)
Denominator:
Weighted average common shares outstanding—basic and diluted	62,040,715		56,412,439
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(4.27)	$	(3.07)

Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:


	As of March 31,
	2021	2020
Options to purchase common shares	8,549,583	9,136,829
Warrants to purchase common shares	106,751	106,751
Restricted share units	1,045,519	483,617
	9,701,853	9,727,197